Neuroendocrinology

Conference Report

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Sorbye H.a · Baudin E.b · Borbath I.c · Caplin M.d · Chen J.e · Cwikla J.B.f · Frilling A.g · Grossman A.h · Kaltsas G.i · Scarpa A.j · Welin S.k · Garcia-Carbonero R.l · ENETS 2016 Munich Advisory Board Participants

Author affiliations

aDepartment of Oncology and Clinical Science, Haukeland University Hospital, Bergen, Norway
bEndocrine Oncology, Gustave Roussy, Villejuif, France
cHepato-Gastroenterology Unit, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
dNeuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, London, United Kingdom
eDepartment of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
fFaculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland
gDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom
hNeuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom
iNational and Kapodistrian University of Athens, Athens, Greece
jARC-Net Centre for Applied Research on Cancer and Section of Pathology of the Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy
kDepartment of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
lOncology Department, Hospital Universitario 12 de Octubre, CNIO, CIBERONC, Universidad Complutense de Madrid, Madrid, Spain

Keywords: Neuroendocrine neoplasmNeuroendocrine tumorNeuroendocrine carcinoma

Related Articles for ""
Neuroendocrinology 2019;108:54–62
https://doi.org/10.1159/000493318

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Conference Report

Received: June 26, 2018
Accepted: August 27, 2018
Published online: August 28, 2018
Issue release date: January 2019

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Abstract

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

© 2018 S. Karger AG, Basel



Related Articles:

References

  1. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System, ed 4. Lyon, IARC Press, 2010.
  2. Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G. Neoplasms of the Neuroendocrine Pancreas, ed 4. Lyon, IARC Press, 2017.
  3. Korse CM, Taal BG, van Velthuysen ML, Visser O: Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013; 49: 1975–1983.
  4. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC: Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014; 120: 2814–2823.
  5. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al: Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22: 657–664.
  6. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al: ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016; 103: 186–194.
  7. Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, et al: Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017; 79: 158–165.
  8. Shafqat H, Ali S, Salhab M, Olszewski AJ: Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum 2015; 58: 294–303.
  9. Mosquera C, Koutlas NJ, Fitzgerald TL: Localized high-grade gastroenteropancreatic neuroendocrine tumors: defining prognostic and therapeutic factors for a disease of increasing clinical significance. Eur J Surg Oncol 2016; 42: 1471–1477.
  10. Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G: Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 2017; 58: 368–379.
  11. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152–160.
  12. Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, et al: Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014; 105: 1176–1181.
  13. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al: The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 2017; 104: 85–93.
  14. Dasari AMK, Byers L, Sorbye H, Yao J: Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162983 Cases. Cancer 2018; 124: 807–815.
  15. Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al: Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 2014; 38: 437–447.
  16. Fitzgerald TL, Mosquera C, Lea CS, McMullen M: Primary site predicts grade for gastroenteropancreatic neuroendocrine tumors. Am Surg 2017; 83: 799–803.
  17. Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nunez B, et al: Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. Journal of the National Cancer Institute 2017, DOI: 10.1093/jnci/djw277.
  18. Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al: Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20: 649–657.
  19. Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P: Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist 2016; 21: 1191–1199.
  20. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C: Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 2012; 36: 601–611.
  21. Fazio N, Milione M: Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev 2016; 50: 61–67.
  22. Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, et al: Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016; 22: 1011–1017.
  23. Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, et al: Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%. Mod Pathol 2017; 30: 587–598.
  24. Girardi DM, Silva ACB, Rêgo JFM, Coudry RA, Riechelmann RP: Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: a systematic review. Cancer Treat Rev 2017; 56(suppl C): 28–35.
  25. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117: 4617–4622.
  26. Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjaer A, et al: Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer 2014; 5: 628–632.
  27. Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, et al: Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015; 22: 289–298.
  28. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology – diagnosis and prognostic stratification. Neuroendocrinology 2017; 105: 196–200.
  29. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al: Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008; 32: 719–731.
  30. Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H, Nakamura N: Histopatholo gy of gastrointestinal neuroendocrine neoplasms. Front Oncol 2013; 3: 2.
  31. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978–985.
  32. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010; 51: 704–712.
  33. La Rosa S, Sessa F, Uccella S: Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol 2016; 27: 284–311.
  34. de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, et al: Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology 2017; 105: 412–425.
  35. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al: The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39: 683–690.
  36. Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, et al: Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res 2017; 23: 4625–4632.
  37. Scoazec JY, Couvelard A, Monges G, Guye­tant S, Bisot-Locard S, Parot X, et al: Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among French pathologists (the PRONET study). Neuroendocrinology 2017; 105: 67–76.
  38. Tang LH, Basturk O, Sue JJ, Klimstra DS: A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016; 40: 1192–1202.
  39. Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, et al: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN): a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 2018; 45: 262–277.
  40. Haugvik SP, Janson ET, Osterlund P, Langer SW, Falk RS, Labori KJ, et al: Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study. Ann Surg Oncol 2016; 23: 1721–1728.
  41. Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, et al: Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery 2016; 159: 862–871.
  42. Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, et al: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. BMC gGastroenterol 2016; 16: 111.
  43. Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, et al: Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol 2013; 37: 949–959.
  44. Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al: Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol 2016; 42: 1464–1470.
  45. Meng MB, Zaorsky NG, Jiang C, Tian LJ, Wang HH, Liu CL, et al: Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 2013; 106: 317–322.
  46. Deng HY, Ni PZ, Wang YC, Wang WP, Chen LQ: Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 2016; 8: 1250–1256.
  47. Oberg K, Knigge U, Kwekkeboom D, Per ren A, Group EGW: Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7):vii124–vii130.
  48. Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103: 172–185.
  49. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, et al: The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010; 39: 799–800.
  50. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al: Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15:e8–e21.
  51. Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, et al: Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol 2017; 43: 1682–1689.
  52. Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al: Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014; 53: 1284–1297.
  53. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al: ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy 2 – chemotherapy. Neuroendocrinology 2017; 105: 281–294.
  54. Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al: FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012; 19: 751–757.
  55. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, et al: Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65: 889–893.
  56. Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, et al: Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology 2013; 97: 331–340.
  57. Catena L, Bajetta E, Milione M, Ducceschi M, Valente M, Dominoni F, et al: Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Target Oncol 2011; 6: 65–68.
  58. Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, et al: Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas 2017; 46: 302–305.
  59. Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al: Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015; 42: 176–185.
  60. Armaghany T, Vahdati G, Thamake S, Hamidi M, Amerinia R, Delpassand E: Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): retrospective analysis in a single referral center. J Clin Oncol 2015; 33:e15175.
  61. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al: PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med 2016; 374: 2542–2552.
  62. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374–1385.
  63. Volante M, Monica V, Birocco N, Brizzi MP, Busso S, Daniele L, et al: Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas. Neuroendocrinology 2015; 101: 151–160.
  64. Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M, et al: Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch 2013; 462: 47–56.
  65. Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al: Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer 2015; 22: 35–45.
  66. Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al: Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol 2015; 16:e435–e446.
  67. Karkouche R, Bachet JB, Sandrini J, Mitry E, Penna C, Cote JF, et al: Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways: a clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol 2012; 24: 1430–1437.
  68. Woischke C, Schaaf CW, Yang HM, Vieth M, Veits L, Geddert H, et al: In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol 2017; 30: 95–103.
  69. Takizawa N, Ohishi Y, Hirahashi M, Takahashi S, Nakamura K, Tanaka M, et al: Molecular characteristics of colorectal neuro­endocrine carcinoma; similarities with ad­enocarcinoma rather than neuroendocrine tumor. Hum Pathol 2015; 46: 1890–1900.
  70. Shida T, Furuya M, Nikaido T, Kishimoto T, Koda K, Oda K, et al: Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clinical Cancer Res 2005; 11: 450–458.
  71. La Rosa S, Marando A, Gatti G, Rapa I, Volante M, Papotti M, et al: Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Hum Pathol 2013; 44: 1391–1399.
  72. Bergsland EK, Roy R, Stephens P, Ross JS, Bailey M, Olshen A: Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas: a new clinicopathologic entity. J Clin Oncol 2016; 34: 4020.
  73. Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, et al: Genomic profiling of metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in the personalized-medicine era. J Cancer 2016; 7: 1044–1048.
  74. Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML: Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis 2017; 8:e3004.
  75. Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al: NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer 2016; 138: 927–938.
  76. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al: Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017; 18: 42–51.
  77. Siravegna G, Marsoni S, Siena S, Bardelli A: Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017; 14: 531–548.
  78. Zatelli MC, Grossrubatscher EM, Guadagno E, Sciammarella C, Faggiano A, Colao A: Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms. Endocr Relat Cancer 2017; 24:R223–R237.

Article / Publication Details

First-Page Preview
Abstract of Conference Report

Received: June 26, 2018
Accepted: August 27, 2018
Published online: August 28, 2018
Issue release date: January 2019

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2019, Vol.108, No. 1

January 2019

Article

Recommend This
TOP